Search results
Results from the WOW.Com Content Network
Rasheda Ali on National and Local News: BrainStorm's ALS Clinical Trial Results Exceeded Expectations NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (OTCQB: BCLI ...
This page was last edited on 4 February 2025, at 10:37 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
The institute has raised and spent more than $100 million on research into effective treatments for ALS and practices open-source science. [19] After the discovery that the multiple sclerosis drug Gilenya might also be a treatment for ALS, the Institute enrolled 30 people in a Phase 2A clinical trial the drug in 2013, though it did not progress further.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
BrainStorm's Outstanding ALS Clinical Data Chosen to Kick-Off the Israel Neurological Association Meeting NEW YORK & PETACH TIKVA, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (OTC.QB ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
The ALSFRS-R is the most frequently used outcome measure in clinical trials [39] and is used by doctors to track disease progression. [40] Though the degree of variability is high and a small percentage of people have a much slower progression, on average people with ALS lose about 1 ALSFRS-R point per month. [41]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more